Neurocrine Biosciences (NASDAQ:NBIX) PT Raised to $128.00
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price raised by Royal Bank of Canada from $123.00 to $128.00 in a report released on Wednesday morning, Benzinga reports. They currently have a sector perform rating on the stock. A number of other equities analysts have also recently commented on the company. Raymond James boosted […]
More Stories
Avondale Wealth Management Has $211,000 Holdings in Permian Basin Royalty Trust (NYSE:PBT)
Avondale Wealth Management boosted its stake in Permian Basin Royalty Trust (NYSE:PBT – Free Report) by 100.0% in the fourth...
Alpha Architect 1-3 Month Box ETF (BATS:BOXX) Stock Position Boosted by Avondale Wealth Management
Avondale Wealth Management grew its position in Alpha Architect 1-3 Month Box ETF (BATS:BOXX – Free Report) by 379.2% in...
ORG Partners LLC Increases Holdings in iShares 20+ Year Treasury Bond ETF (NASDAQ:TLT)
ORG Partners LLC raised its stake in iShares 20+ Year Treasury Bond ETF (NASDAQ:TLT – Free Report) by 325.6% during...
ORG Partners LLC Raises Holdings in India Internet & Ecommerce ETF (NYSEARCA:INQQ)
ORG Partners LLC boosted its stake in shares of India Internet & Ecommerce ETF (NYSEARCA:INQQ – Free Report) by 15.6%...
ORG Partners LLC Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)
ORG Partners LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 0.3% in the...
ORG Partners LLC Boosts Stock Position in iShares Core MSCI Emerging Markets ETF (NYSEARCA:IEMG)
ORG Partners LLC raised its holdings in iShares Core MSCI Emerging Markets ETF (NYSEARCA:IEMG – Free Report) by 5.2% during...